Ascendis Pharma’s Strategic Partnership with Novo Nordisk
Ascendis Pharma A/S announced that it has granted Novo Nordisk A/S an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary ...
Wells Fargo analyst Derek Archila maintained a Buy rating on Ascendis Pharma (ASND – Research Report) yesterday and set a price target of ...
The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...
Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of ...
Buying $100 In ASND: If an investor had bought $100 of ASND stock 15 years ago, it would be worth $5,581.08 today based on a ...
Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with ...
On Monday, Ascendis Pharma A/S (NASDAQ:ASND) granted Novo Nordisk A/S (NYSE:NVO) an exclusive worldwide license. The pact ...
Novo Nordisk ( NVO, Financials) entered an exclusive agreement with Ascendis Pharma ( ASND, Financials) to license Ascendis's TransCon technology platform for developing novel treatments targeting ...
In a report released today, Li Watsek from Cantor Fitzgerald maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback